<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Hims &amp; Hers launches new peptide treatments — Live Feed</title><link>https://www.live-feeds.com/feed/hims-hers-launches-new-peptide-treatments</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/hims-hers-launches-new-peptide-treatments/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Hims &amp; Hers launches Peptides+ longevity platform with five compounded treatments</title><link>https://www.live-feeds.com/feed/hims-hers-launches-new-peptide-treatments</link><guid isPermaLink="false">https://www.live-feeds.com/feed/hims-hers-launches-new-peptide-treatments#u212590</guid><pubDate>Sat, 21 Nov 2026 22:37:52 +0000</pubDate><description>Hims &amp;amp; Hers has launched Peptides+, a new clinically guided specialty offering five compounded peptide treatments for longevity and proactive health. The platform expands the company&amp;#039;s compounding business beyond weight loss into personalized wellness care with ongoing medical support. Hers, the women&amp;#039;s health brand, is positioning Peptides+ to lead in injectable longevity treatments. The launch occurs under an October HHS policy framework. Noom simultaneously launched OpenRx, a competing peptide and preventive health brand, signaling growing mainstream interest in experimental p</description></item>
</channel></rss>